Urology
Latest news
133 articles · 20 / page
Maryland’s Global Budget Revenue Model Was Linked to Better Cancer Surgery Outcomes and Lower Medicare Spending
In a large Medicare study, hospitals under Maryland’s global budget model showed modest but significant improvements in cancer surgery outcomes, driven by fewer complications and shorter stays, with lower inpatient spending.
Testosterone and Weight Loss: Decoding the Link Between Sex Hormones and Cardiovascular Risk in Men with Type 2 Diabetes
A longitudinal analysis of the Look AHEAD trial demonstrates that baseline testosterone and weight loss-induced changes in SHBG significantly modulate cardiovascular risk in men with type 2 diabetes, highlighting the critical role of hormon
Navigating Scrotal Health: A Comprehensive Guide to Lymphedema and Excessive Sweating
This article provides an in-depth exploration of scrotal lymphedema and hyperhidrosis, detailing their physiological causes, clinical symptoms, and the latest management strategies for both patients and healthcare providers.
Questioning Routine Hormone Therapy: No Survival Benefit for Low-PSA Recurrent Prostate Cancer Undergoing Postoperative Radiotherapy
A large-scale individual patient data meta-analysis suggests that adding hormone therapy to postoperative radiotherapy does not improve overall survival for patients with low PSA levels, prompting a re-evaluation of current treatment standa
SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Enable Bladder Preservation in Muscle-Invasive Disease
The SURE-02 phase 2 trial demonstrates that a combination of sacituzumab govitecan and pembrolizumab achieves a 39% clinical complete response rate in muscle-invasive bladder cancer, offering a promising bladder-sparing alternative for pati
Risk Stratification in PSMA PET-Staged Oligorecurrent Prostate Cancer: Clinical Synthesis of the PORTAL Nomogram and Metastasis-Directed Therapy
This review analyzes the PORTAL study’s nomogram for predicting ADT-free survival in oligorecurrent prostate cancer, synthesizing evidence on PSMA PET-guided SBRT and the clinical utility of risk-based patient selection.
Telesurgery Breaks the Distance Barrier: Landmark RCT Confirms Non-Inferiority to Local Robotic Urology
A multicentre randomized controlled trial demonstrates that robotic telesurgery over distances up to 2800 km is non-inferior to local surgery for urological procedures, maintaining high success rates, low latency, and equivalent safety prof
Perioperative Enfortumab Vedotin and Pembrolizumab: A Practice-Changing Advance for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
The Phase 3 KEYNOTE-905/EV-303 trial demonstrates that perioperative enfortumab vedotin plus pembrolizumab significantly improves event-free survival (HR 0.40) and overall survival (HR 0.50) compared to surgery alone in cisplatin-ineligible
Salvage Focal Therapy vs. Radical Prostatectomy: Comparable 10-Year Survival with Dramatically Reduced Morbidity
A landmark multicenter study indicates that salvage focal therapy (sFT) achieves long-term cancer-specific survival comparable to salvage radical prostatectomy (sRP) while significantly lowering the risk of major perioperative complications
Metastasis-Directed Therapy Delivers Clear Progression Benefits in Oligometastatic Prostate Cancer: The WOLVERINE IPD Meta-Analysis
The WOLVERINE individual patient data meta-analysis confirms that metastasis-directed therapy significantly improves progression-free and castration resistance-free survival in oligometastatic prostate cancer, providing high-level evidence
Docetaxel Rechallenge vs Cabazitaxel: Choosing the Right Taxane Sequence in Metastatic Castration-Resistant Prostate Cancer
A retrospective cohort study of 669 veterans suggests that docetaxel rechallenge provides a significant survival benefit compared to cabazitaxel for patients with metastatic castration-resistant prostate cancer who previously responded to d
Low Baseline PSA Predicts Exceptional Long-Term Safety: A 20-Year Paradigm Shift in Prostate Cancer Screening
A 20-year cohort study shows that baseline PSA levels in men aged 45-70 are highly predictive of long-term prostate cancer risk, with PSA
PGT-A for Severe Male Infertility: Reducing Pregnancy Loss Without Boosting Live Birth Rates
A multicentre RCT published in the BMJ demonstrates that while PGT-A does not increase cumulative live birth rates for couples with severe male infertility, it significantly reduces the risk of pregnancy loss, providing a nuanced framework
Atezolizumab and BCG Combination Fails to Improve Event-Free Survival in High-Risk NMIBC: Results from the ALBAN Phase III Trial
The Phase III ALBAN trial found that adding atezolizumab to BCG therapy did not improve event-free survival in BCG-naive high-risk non-muscle-invasive bladder cancer, highlighting the complexity of immune checkpoint inhibitor synergy in thi
Breakthroughs in Prostate Cancer: Insights from the MetaCURE Multi-Modal Trial
The MetaCURE trial demonstrates that combining surgery, radiation, and advanced hormonal therapies can achieve deep responses in high-risk prostate cancer, paving the way for faster drug development through intermediate clinical endpoints.
Integrating Automated Radiomics with Serum Biomarkers Redefines Risk Stratification in Metastatic Castration-Resistant Prostate Cancer
This article explores how novel automated imaging tools, combined with clinical biomarkers, enhance risk stratification in mCRPC, while also reviewing the pivotal OS data from abiraterone and enzalutamide trials that inform contemporary tre
Biomarkers of Benefit: tTMB and MSI Status Redefine Immunotherapy Success in Metastatic Castration-Resistant Prostate Cancer
A large-scale clinico-genomic study confirms that both tissue-based TMB and MSI-H independently predict significantly improved outcomes for ICI therapy in metastatic castration-resistant prostate cancer, while also validating blood-based MS
MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer
A large-scale clinico-genomic study demonstrates that both tissue-based MSI-H and TMB-H status independently predict superior outcomes for immune checkpoint inhibitors in mCRPC, while validating blood-based MSI as a viable alternative for p
AHR Inhibition with IK-175: A New Frontier in Overcoming Checkpoint Resistance in Urothelial Carcinoma
This Phase 1/1b study demonstrates that IK-175, an oral AHR inhibitor, is safe and clinically active in PD-1-refractory urothelial carcinoma, showing target engagement and preliminary efficacy both as monotherapy and in combination with niv
Browse by specialty
Open language-specific specialty feeds and department pages.